# An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

> **NCT05469919** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** Ceralasertib

## Key facts

- **NCT ID:** NCT05469919
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-09
- **Primary completion:** 2023-08-17
- **Final completion:** 2024-03-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469919, "An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05469919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*